A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin's Lymphoma (NHL)
Phase of Trial: Phase I/II
Latest Information Update: 13 Dec 2018
At a glance
- Drugs LOXO-305 (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Loxo Oncology
- 06 Dec 2018 Status changed from not yet recruiting to recruiting.
- 12 Nov 2018 Status changed from planning to not yet recruiting.
- 08 Nov 2018 According to a Loxo Oncology media release,Enrollment of First Patient in LOXO-305 Phase 1/2 Study on Track for Fourth Quarter 2018.